Jump to content

Anti-CD3 monoclonal antibody

Edit links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Monkbot (talk | contribs) at 02:35, 29 April 2015 (Task 7: replace et al. in author/editor parameters with |display-authors=etal or |display-editors=etal;). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

An Anti-CD3 monoclonal antibody is one that binds to CD3 on the surface of T cells. They are immunosuppresive drugs.

The first to be approved was muromonab-CD3 in 1986, to treat transplant rejection.

Newer monoclonal antibodies with the same mechanism of action include otelixizumab, teplizumab and visilizumab. They are being investigated for the treatment of other conditions like Crohn's disease, ulcerative colitis and type 1 diabetes,[1] and for inducing immune tolerance.[2][3]

Mechanism

See muromonab-CD3.

See also

References

  1. ^ Herold KC, Taylor L. (2003). "Treatment of Type 1 diabetes with anti-CD3 monoclonal antibody: induction of immune regulation?". Immunologic Research. 28 (2): 141–50. doi:10.1385/IR:28:2:141. PMID 14610290.
  2. ^ Bisikirska; et al. (2005). "TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs". {{cite journal}}: Cite journal requires |journal= (help)
  3. ^ Bisikirska & Herold; Herold, Kevan C. (2004). "Use of Anti-CD3 Monoclonal Antibody to Induce Immune Regulation in Type 1 Diabetes". Annals of the New York Academy of Sciences. 1037: 1–9. doi:10.1196/annals.1337.001. PMID 15699486.


Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Anti-CD3_monoclonal_antibody&oldid=659794352"